Most Americans don’t spend much time thinking about Medicare until they need it. Then, suddenly, the rules, the ratings, the coverage gaps, and the plan options feel enormous. Right now, that calculus is shifting again, and the changes are real. Not just paperwork reshuffling.
In April 2026, federal health officials finalized sweeping updates to Medicare Advantage (Part C) and Medicare Part D prescription drug coverage, all of which take effect in January 2027. Some of those updates could save beneficiaries hundreds of dollars a year. Others quietly chip away at protections that many enrollees don’t even realize they have. Knowing what’s changing before open enrollment season begins gives you a real advantage.
Whether you’re approaching Medicare eligibility, already enrolled, or helping a parent or partner understand their options, this breakdown covers the five most consequential shifts and what each one actually means for your coverage.
1. How Your Plan Is Graded Is Getting a Major Overhaul
Medicare Advantage plans are rated on a one-to-five-star scale every year. Those stars aren’t just decorations. High-performing plans qualify for quality bonus payments, which can be used to reduce cost sharing, cover extra benefits, or fund supplemental coverage not offered by traditional Medicare. The rating a plan earns directly affects what you get for your premium dollar.
The new 2027 rule eliminates 11 star ratings metrics that measured administrative processes on which plans tended to perform similarly. The Centers for Medicare and Medicaid Services (CMS) argued that these metrics didn’t help beneficiaries tell better plans from worse ones, and removing them allows the system to refocus on clinical outcomes and patient experience. The agency had originally proposed removing 12 measures, but the “diabetes care – eye exam” measure was kept after the comment period.
A new depression screening and follow-up measure is being added to address behavioral health gaps, beginning with the 2027 measurement year and reflected in 2029 star ratings. That’s a notable step for a program that has historically underweighted mental health metrics.
One of the bigger structural changes involves how consistently top performers are rewarded. CMS is not implementing a new health equity award that had been put in place by the previous administration and was set to kick in in 2027. Instead, the agency reinstated a bonus system that raises payments to plans with consistently high ratings. Critics point out this rolls back targeted incentives for improving care among lower-income and medically vulnerable enrollees. Supporters say the historical reward factor applies fairly across the entire patient population. CMS projects these combined star ratings changes will increase Medicare spending by $13.8 billion between 2027 and 2036, with the largest increases hitting in 2028 and 2029.
For beneficiaries, the practical implication is straightforward: the plans that score highest may look different in 2027 than they did in prior years. When open enrollment opens in October, don’t assume your current plan’s rating is the same as it was last year. Pull up the updated comparisons on Medicare.gov and check clinical quality scores, not just the star total.
2. Key Prescription Drug Protections Are Being Made Permanent
This is one of the most consumer-friendly changes in the entire rule, even though it sounds like bureaucratic housekeeping. Here’s why it matters.
The Inflation Reduction Act of 2022 gave CMS temporary authority through 2026 to implement major Part D drug benefit changes through program instructions. With that authority expiring, CMS is now codifying those changes for 2027 and beyond. That’s the difference between a protection that could technically disappear and one written permanently into federal regulation.
The coverage gap phase, widely known as the “donut hole,” has been eliminated, and beneficiary out-of-pocket spending on covered Part D drugs is now capped at $2,000 per year. To understand why this matters, consider where things stood before. The 2025 annual out-of-pocket maximum is $2,000, down from $8,000 in 2024. For people on expensive specialty drugs, that’s not a rounding error. It’s potentially thousands of dollars per year in savings.
What CMS finalized for 2027 codifies all of this permanently, including eliminating the coverage gap phase, establishing the reduced annual out-of-pocket threshold, removing cost sharing for enrollees in the catastrophic phase, and incorporating the Manufacturer Discount Program that replaced the earlier Coverage Gap Discount Program on January 1, 2025. CMS is also locking in updates to how out-of-pocket cost calculations work, specialty-tier rules, and other payment mechanics.
One change that affects more enrollees than most people realize: about 11 million Part D enrollees are expected to reach the $2,000 cap, with average out-of-pocket savings of roughly $600 per person. For those who don’t receive low-income assistance, savings average closer to $1,100. The 2027 rule makes those protections a permanent floor rather than a temporary arrangement that required annual renewal.
If you take any prescription medications regularly, especially for chronic conditions like diabetes, heart disease, or cancer, this change is worth paying close attention to during open enrollment. Compare plans using the Medicare Plan Finder at Medicare.gov, which estimates your total yearly costs based on your specific drugs.
3. Tighter Rules Around Supplemental Benefits, Including a Cannabis Clarification
Supplemental benefits are the extras that Medicare Advantage plans can offer beyond traditional Medicare coverage: things like dental care, vision, over-the-counter allowances, and fitness programs. They’re popular. They’re also frequently confusing, and in some cases, they’ve been used in ways regulators didn’t intend.
The 2027 rule finalizes two supplemental benefit policies that had been proposed the prior year. The first strengthens eligibility requirements for Special Supplemental Benefits for the Chronically Ill (SSBCI) and requires plans to publicly post their eligibility criteria. The second codifies requirements for administering supplemental benefits through debit cards, including that cards be electronically linked to plan-covered items through a real-time verification mechanism at the point of sale, and that cards be limited to the specific plan year.
Why the debit card restrictions? CMS noted that enrollees frequently express confusion about what can be purchased with their plan debit card, and that stakeholders raised concerns these cards could be used to purchase items not covered by the plan. CMS also indicated that debit cards may be subject to fraud in the absence of stronger guardrails on non-covered items. The new verification requirement means that when you swipe your supplemental benefits card at the pharmacy or grocery store, the system will confirm in real time whether the item is actually covered, much like a health savings account card works today.
The rule also finalizes a clarification that cannabis products illegal under state or federal law are not allowable as SSBCI benefits. The final rule refines the existing prohibition, narrowing it to products that violate governing state or federal law, thereby preserving access to certain lawful hemp-derived products as eligible benefits. If you currently have a Medicare Advantage plan that includes cannabis-related benefits, check with your plan for 2027 to confirm whether those benefits remain intact.
One protection that was removed alongside these guardrails: the obligation for plans to send mid-year communications reminding enrollees of supplemental benefits they haven’t yet used has been eliminated. That notice, while modest, helped people actually access benefits they were paying for. Going forward, review your plan’s full supplemental benefit package every January so nothing goes unused.
4. A Broad Rollback of Regulatory Protections
Not all of the 2027 rule changes benefit beneficiaries. A significant portion of the final rule is dedicated to deregulation, reducing requirements on Medicare Advantage plans and their marketing partners. Some of these rollbacks are genuinely administrative in nature. Others have more visible impacts on coverage and consumer protection.
The new rule eliminates or relaxes several marketing and enrollment safeguards, including the 48-hour Scope of Appointment waiting period and the 12-hour educational-to-marketing event prohibition. Most of those changes take effect October 1, 2026. In plain English: under the previous rules, agents had to wait 48 hours after a beneficiary signed an interest form before meeting with them, and certain events couldn’t immediately pivot from an “educational” format to a direct sales pitch. Both of those restrictions are now gone.
The final rule also removes State Health Insurance Assistance Programs (SHIPs) from the list of resources brokers must offer to beneficiaries for further information during sales calls. SHIPs are free, unbiased counseling programs that help people navigate Medicare options. Removing them from that required list makes it less likely that beneficiaries in high-pressure sales situations will be pointed toward impartial help.
The rule also finalizes four health equity rollbacks. Utilization management committees will no longer be required to include a health equity expert member, conduct annual health equity analyses, or post those analyses publicly. These requirements had been put in place to systematically track whether Medicare Advantage plans were serving all enrollees equitably, including those with lower incomes or disabilities. Their removal means less structured oversight of how well plans serve their most vulnerable members.
Medicare Advantage still covers 35 million seniors, more than half of all Medicare beneficiaries. For a program that large, the consumer protection details matter. If you’re in a Medicare Advantage plan or considering one, understanding what oversight protections exist and which ones have been removed is important context when comparing your options.
5. An Executive Order Is Reshaping Medicare Rules From the Top Down
The deregulatory provisions described above didn’t emerge from internal CMS program review alone. They’re part of a deliberate, administration-wide policy direction, and that context matters for understanding how Medicare could continue to change beyond 2027.
On January 31, 2025, President Trump signed Executive Order 14192, “Unleashing Prosperity Through Deregulation.” The order directed federal agencies to repeal ten regulations for every new regulation issued.
The 2027 Medicare rule pursues a broad deregulatory agenda aligned with Executive Order 14192, reversing marketing and enrollment safeguards introduced in 2023 and easing documentation and reporting obligations. CMS cited the executive order by name in its press release as the driving force behind the removal of several existing Medicare requirements.
What does this mean in practice? The push to deregulate was evident in certain Medicare Advantage marketing rules, where CMS reversed several Biden-era rules aimed at regulating the marketing of MA plans. Medicare beneficiaries have long reported receiving an overabundance of advertising from MA plans and third-party marketing organizations. There has been clear evidence that misleading marketing materials have resulted in increased confusion, and for some, enrollment in MA plans without the beneficiaries’ knowledge.
The 2027 final rule removes the 48-hour waiting period between a beneficiary signing a Scope of Appointment form and meeting with an agent. It also removed restrictions on the use of superlatives like “best” or “top-rated” in marketing materials. Previous rules restricted those terms unless plans could substantiate the claims. The new rule removes those restrictions, arguing that broader prohibitions against misleading information already provide sufficient oversight.
For beneficiaries, the practical result is an environment with fewer formal guardrails between you and high-pressure insurance marketing. That doesn’t mean all plans are bad actors. Many are not. But it does mean you need to do more of your own homework. Seek out SHIPs counselors in your state, use Medicare’s official plan comparison tools, and be skeptical of any unsolicited outreach claiming one plan is simply “best.”
Read More: A Father Was Diagnosed With Dementia and Medicare’s Response Was Just Bizarre
What This Means for You
These regulations became effective June 1, 2026, and apply to coverage beginning January 1, 2027. That means open enrollment this fall, running October 15 through December 7, is your window to act. There are five things worth doing before you choose or renew a plan for 2027.
First, check the updated star ratings for your current plan at Medicare.gov once they’re released. The scoring system changed, and a plan that rated well in 2026 may look different under the new methodology. Second, if you take ongoing prescriptions, run your drug list through the Medicare Plan Finder to see how the codified Part D cap affects your estimated annual spending, especially if you’re on specialty medications. Third, understand exactly what supplemental benefits your plan offers and whether the new debit card rules change how you access them. Fourth, if you receive any sales calls or marketing materials, remember that the 48-hour waiting period between initial contact and enrollment discussions no longer exists. Take your time regardless. And fifth, find your local SHIP (State Health Insurance Assistance Program) before enrollment season. It’s free, unbiased, and staffed by people trained to help you compare plans without any sales incentive.
As CMS Director Chris Klomp put it, the agency believes it is “fundamentally shifting” its approach to quality. Whether you agree with every aspect of that shift or not, the changes are real and they start in 2027. The beneficiaries who fare best are the ones who go into open enrollment informed rather than simply re-enrolling by default. The rules have changed. Your approach to open enrollment should too.
Disclaimer: This information is not intended to be a substitute for professional financial advice, investment advice, tax advice, or legal advice, and is provided for informational purposes only. Always seek the guidance of a qualified financial advisor, accountant, or other licensed professional regarding your personal financial situation or investment decisions. Do not make financial, investment, or tax decisions based solely on information presented here. Past performance is not indicative of future results, and all investments carry risk, including the potential loss of principal.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: Free CBD Through Medicare? Here’s What Seniors Need to Know